Helping to inform the world about new developments in Cancer.

Lung Cancer therapy to double life expectancy, a drug called Nivolumab

x-ray-image-568241_1280

Lung Cancer therapy to double life expectancy, a drug called Nivolumab

Reported in the media today, a drug called Nivolumab has been developed to help fight cancer.  Nivolumab acts as an immunomodulator by blocking ligand activation of the cell.

Cancer is quite clever and can “hide” from our immune system, this stops that happening and allows our immune system to see the cancer and attack it.

As reported in top ten deadliest cancers it’s right up there as one of the biggest killers. I wish I had never smoked, and happy that I stopped.




The study was conducted by the American Society of Clinical Oncology, Patients with advanced melanoma enrolled between 2008 and 2013 received nivolumab every 2 weeks for up to 96 weeks and saw an overall survival.

The media are reporting and “milestone” and “doubling life expectancy” in some patients. It’s a pity they have to make it sound like an all out cure. It increases your time here. So it is a positive but I don’t think we can expect it to give us an extra 50 years.

How it works

The drug works by allowing our immune system to attack the cancer, it’s programmed to block antibodies used for the treatment of melanoma and for the treatment of non-small lung cancer. In contrast to traditional chemotherapies and targeted anti-cancer therapies, which exert there effects by inhibiting the tumor growth. Nivolumab acts by inducing the immune system to attack the tumour. So it appears to free up the immune system only around the tumour, rather than more generally, which could mean fewer side affects.

hela-cells-544318_1280

The clinical trail

The trail started in 2009 and completed in 2013, study period from 2013 till 2015 is now complete.

The Primary Outcome Measures:

  • To characterize the safety and tolerability of multiple doses of BMS-936558 (MDX-1106) [ Time Frame: 70 days post last dose of study drug ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

  • Immunogenicity of multiple doses of BMS-936558 [ Time Frame: up to 12 eight (8) week cycles ] [ Designated as safety issue: No ]
  • Pharmacokinetic (PK) profile of multiple doses of BMS-936558 [ Time Frame: Samples collection for PK analysis through Cycle 3 (first 24 weeks) of study therapy. ] [ Designated as safety issue: No ]
  • Assess the efficacy of BMS-936558 (MDX-1106) as monotherapy [ Time Frame: Every 8 weeks throughout study participation. ] [ Designated as safety issue: No ]
  • The dose response relationship in melanoma and in NSCLC [ Time Frame: 56 of each cycle (up to cycle 18) and if available including off-study and follow-up visits (approximately up to 46 weeks) ] [ Designated as safety issue: No ]
  • Measures of humoral and cellular immune responses to tumour antigens and recall responses to non-tumour antigens such as T cell reactivity against melanoma peptides [ Time Frame: Day 1 of each cycle (up to cycle 18) and if available including off-study and follow-up visits (approximately up to 46 weeks) ] [ Designated as safety issue: No ]
    These will be measured only at selected study sites and for subsets of selected tumours, and are very exploratory in nature

https://clinicaltrials.gov/show/NCT00730639

Approval

It’s great to see a improvement in the life expectancy of anyone with cancer, if they are taking this drug. It’s been approved for america but I’m not sure if it’s approved for Britian yet.